2019
DOI: 10.1016/j.xphs.2019.05.001
|View full text |Cite
|
Sign up to set email alerts
|

Optimization of Nanostructured Lipid Carriers of Lurasidone Hydrochloride Using Box-Behnken Design for Brain Targeting: In Vitro and In Vivo Studies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
32
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 83 publications
(32 citation statements)
references
References 25 publications
0
32
0
Order By: Relevance
“…This phenomenon can be explained by the rapid solidification of the solid lipids during the formation of the NLC, which results in nanoparticles with an internal core containing a low amount of liquid lipids, which in turn accumulate in the outermost layers. As rivastigmine is an oil, it also tends to accumulate on the surface of the NLC, meaning it is released more quickly [ 33 , 99 , 101 ].…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…This phenomenon can be explained by the rapid solidification of the solid lipids during the formation of the NLC, which results in nanoparticles with an internal core containing a low amount of liquid lipids, which in turn accumulate in the outermost layers. As rivastigmine is an oil, it also tends to accumulate on the surface of the NLC, meaning it is released more quickly [ 33 , 99 , 101 ].…”
Section: Resultsmentioning
confidence: 99%
“…For instance, the release of teriflunomide from a NLC intranasal formulation in simulated nasal electrolyte solution followed a biphasic behavior, with 75.11% of the drug being released after 8 h. Similar values were observed for the optimized rivastigmine-loaded NLC produced by ultrasound technique (75.89%) after the same period of time and using the same dissolution media ( Figure 5 ) [ 31 ]. Jazuli et al conducted drug release studies with lurasidone-loaded NLCs for nose-to-brain delivery and observed fast drug release after 12 h followed by sustained drug release, with a maximum release of 92.12% after 24 h [ 101 ]. This biphasic behavior was also observed with both optimized rivastigmine-loaded NLC formulations ( Figure 4 and Figure 5 ), although the maximum drug release was observed after 48 h. Alam et al observed sustained in vitro release of isradipine from a NLC, with a maximum value of 92.89% after 24 h [ 46 ], which was also observed for the rivastigmine release from the optimized NLC produced by HPH (93.55%) after 24 h ( Figure 5 ).…”
Section: Resultsmentioning
confidence: 99%
“…17,19,23 Recently, NLCs have been widely employed as a promising delivery system for brain targeting of versatile drugs via the nasal route. 8,24,25 In this work, the potential of employing nanostructured lipid carriers loaded in situ gel for enhancing nose-to-brain delivery of FLB has been explored. Box-Behnken design was applied for optimization of FLB-NLCs.…”
Section: Introductionmentioning
confidence: 99%
“…Furthermore, the insignicant lack of t value (p if > 0.05) highlights the adequacy of all response surfaces. [18][19][20] 3.1.2 Effect of independent variables on particle size and encapsulation efficiency. The effect of each independent variable on particle size is described by eqn (6) and shown in the corresponding 3D response surface plots (Fig.…”
Section: Resultsmentioning
confidence: 99%